Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)
-
Shares outstanding
-
239,647,920
-
Total 13F shares
-
50,481,130
-
Share change
-
-3,121,091
-
Total reported value
-
$4,974,375,396
-
Put/Call ratio
-
139%
-
Price per share
-
$98.62
-
Number of holders
-
253
-
Value change
-
-$319,748,638
-
Number of buys
-
103
-
Number of sells
-
123
Institutional Holders of BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) as of Q3 2025
As of 30 Sep 2025,
BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) was held by
253 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,481,130 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, FMR LLC, T. Rowe Price Investment Management, Inc., FLOSSBACH VON STORCH SE, PRIMECAP MANAGEMENT CO/CA/, Dodge & Cox, Pfizer Inc, Temasek Holdings (Private) Ltd, Capital International Investors, and BNP PARIBAS FINANCIAL MARKETS.
This page lists
253
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.